EdenteV2, Main, Exploration, bibRecord, 00C055

Salivary concentrations of hexamethylene bisacetamide ( HMBA ) in patients receiving 5-day continuous infusions

Identifieur interne : 00C055 ( Main/Exploration ); précédent : 00C054; suivant : 00C056

Salivary concentrations of hexamethylene bisacetamide ( HMBA ) in patients receiving 5-day continuous infusions

Auteurs : Barbara A. Conley [États-Unis] ; Merrill J. Egorin [États-Unis] ; Eleanor G. Zuhowski [États-Unis] ; Victoria J. Sinibaldi [États-Unis] ; Douglas E. Peterson [États-Unis]

Source :

Cancer Chemotherapy and Pharmacology [ 0344-5704 ] ; 1988-07-01.

RBID : ISTEX:ED1E082857C04018E4B5D84A96BCAE000213068C

English descriptors

Abstract

Summary: Salivary and plasma concentrations of hexamethylene bisacetamide (HMBA) were studied to determine (1) how the concentrations of HMBA achieved in saliva compared with those required to induce differentiation in vitro, and (2) whether saliva might substitute for plasma as a biologic fluid on which to base dosage adjustment. Plasma and expectorated saliva were collected concomitantly from 16 patients receiving 5-day continuous infusions of HMBA. The concentrations of HMBA in each fluid were determined by gas chromatography. The patients displayed a range of periodontal disease from gingivitis to complete edentia, but periodontal disease status did not appear to influence the salivary behavior of HMBA, which mirrored that of the drug in plasma, with concentrations of HMBA increasing in both fluids during the first 12–16 h of infusion. Between 24 and 120 h, HMBA concentrations in saliva and plasma remained constant. In some patients, salivary HMBA concentrations lagged behind those in plasma during the first 6–8 h of infusion, but after that the salivary HMBA concentrations approximated those in the plasma. Salivary concentrations of HMBA between 0.96 and 2.56 mM were associated with nontoxic plasma concentrations of HMBA. Therefore, in patients with restricted venous access, saliva might be a suitable substitute for plasma if adaptive control-dosing schemes for HMBA are employed. Moreover, the concentrations of HMBA in saliva bathing the oral cavity are quantitatively comparable to those required for induction of cell differentiation in vitro.

Url:

https://api.istex.fr/document/ED1E082857C04018E4B5D84A96BCAE000213068C/fulltext/pdf

DOI: 10.1007/BF00254184

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 007562
to stream Istex, to step Curation: 007562
to stream Istex, to step Checkpoint: 005A34
to stream Main, to step Merge: 00C827
to stream Main, to step Curation: 00C055

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Salivary concentrations of hexamethylene bisacetamide ( HMBA ) in patients receiving 5-day continuous infusions</title>
<author><name sortKey="Conley, Barbara A" sort="Conley, Barbara A" uniqKey="Conley B" first="Barbara A." last="Conley">Barbara A. Conley</name>
</author>
<author><name sortKey="Egorin, Merrill J" sort="Egorin, Merrill J" uniqKey="Egorin M" first="Merrill J." last="Egorin">Merrill J. Egorin</name>
</author>
<author><name sortKey="Zuhowski, Eleanor G" sort="Zuhowski, Eleanor G" uniqKey="Zuhowski E" first="Eleanor G." last="Zuhowski">Eleanor G. Zuhowski</name>
</author>
<author><name sortKey="Sinibaldi, Victoria J" sort="Sinibaldi, Victoria J" uniqKey="Sinibaldi V" first="Victoria J." last="Sinibaldi">Victoria J. Sinibaldi</name>
</author>
<author><name sortKey="Peterson, Douglas E" sort="Peterson, Douglas E" uniqKey="Peterson D" first="Douglas E." last="Peterson">Douglas E. Peterson</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:ED1E082857C04018E4B5D84A96BCAE000213068C</idno>
<date when="1988" year="1988">1988</date>
<idno type="doi">10.1007/BF00254184</idno>
<idno type="url">https://api.istex.fr/document/ED1E082857C04018E4B5D84A96BCAE000213068C/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">007562</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">007562</idno>
<idno type="wicri:Area/Istex/Curation">007562</idno>
<idno type="wicri:Area/Istex/Checkpoint">005A34</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">005A34</idno>
<idno type="wicri:doubleKey">0344-5704:1988:Conley B:salivary:concentrations:of</idno>
<idno type="wicri:Area/Main/Merge">00C827</idno>
<idno type="wicri:Area/Main/Curation">00C055</idno>
<idno type="wicri:Area/Main/Exploration">00C055</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Salivary concentrations of hexamethylene bisacetamide ( HMBA ) in patients receiving 5-day continuous infusions</title>
<author><name sortKey="Conley, Barbara A" sort="Conley, Barbara A" uniqKey="Conley B" first="Barbara A." last="Conley">Barbara A. Conley</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Developmental Therapeutics, University of Maryland Cancer Center, 21201, Baltimore, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Medical Oncology, Department of Medicine, University of Maryland School of Medicine, 21201, Baltimore, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Egorin, Merrill J" sort="Egorin, Merrill J" uniqKey="Egorin M" first="Merrill J." last="Egorin">Merrill J. Egorin</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Developmental Therapeutics, University of Maryland Cancer Center, 21201, Baltimore, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Medical Oncology, Department of Medicine, University of Maryland School of Medicine, 21201, Baltimore, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zuhowski, Eleanor G" sort="Zuhowski, Eleanor G" uniqKey="Zuhowski E" first="Eleanor G." last="Zuhowski">Eleanor G. Zuhowski</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Developmental Therapeutics, University of Maryland Cancer Center, 21201, Baltimore, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sinibaldi, Victoria J" sort="Sinibaldi, Victoria J" uniqKey="Sinibaldi V" first="Victoria J." last="Sinibaldi">Victoria J. Sinibaldi</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Developmental Therapeutics, University of Maryland Cancer Center, 21201, Baltimore, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Peterson, Douglas E" sort="Peterson, Douglas E" uniqKey="Peterson D" first="Douglas E." last="Peterson">Douglas E. Peterson</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Oral Diagnosis, University of Maryland Dental School, 21201, Baltimore, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Cancer Chemotherapy and Pharmacology</title>
<title level="j" type="abbrev">Cancer Chemother. Pharmacol.</title>
<idno type="ISSN">0344-5704</idno>
<idno type="eISSN">1432-0843</idno>
<imprint><publisher>Springer-Verlag</publisher>
<pubPlace>Berlin/Heidelberg</pubPlace>
<date type="published" when="1988-07-01">1988-07-01</date>
<biblScope unit="volume">22</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="65">65</biblScope>
<biblScope unit="page" to="68">68</biblScope>
</imprint>
<idno type="ISSN">0344-5704</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0344-5704</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptive control algorithm</term>
<term>Assoc cancer</term>
<term>Biochim biophys acta</term>
<term>Bisacetamide</term>
<term>Blood samples</term>
<term>Cell differentiation</term>
<term>Chromatographic analysis</term>
<term>Clin oncol</term>
<term>Clinical trials</term>
<term>Complete edentia</term>
<term>Continuous infusion</term>
<term>Continuous infusions</term>
<term>Crevicular fluid</term>
<term>Dosage adjustment</term>
<term>Egorin</term>
<term>Erythroleukemic differentiation</term>
<term>Functional differentiation</term>
<term>Hexamethylene</term>
<term>Hexamethylene bisacetamide</term>
<term>Hmba</term>
<term>Infusion</term>
<term>Maryland cancer center</term>
<term>Murine erythroleukemia cells</term>
<term>National cancer institute</term>
<term>Oral cavity</term>
<term>Periodontal disease status</term>
<term>Pharmacokinetic study</term>
<term>Pharmacologic study</term>
<term>Plasma concentrations</term>
<term>Plasma hmba concentrations</term>
<term>Proc natl acad</term>
<term>Saliva</term>
<term>Salivary</term>
<term>Salivary concentrations</term>
<term>Salivary hmba concentrations</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Adaptive control algorithm</term>
<term>Assoc cancer</term>
<term>Biochim biophys acta</term>
<term>Bisacetamide</term>
<term>Blood samples</term>
<term>Cell differentiation</term>
<term>Chromatographic analysis</term>
<term>Clin oncol</term>
<term>Clinical trials</term>
<term>Complete edentia</term>
<term>Continuous infusion</term>
<term>Continuous infusions</term>
<term>Crevicular fluid</term>
<term>Dosage adjustment</term>
<term>Egorin</term>
<term>Erythroleukemic differentiation</term>
<term>Functional differentiation</term>
<term>Hexamethylene</term>
<term>Hexamethylene bisacetamide</term>
<term>Hmba</term>
<term>Infusion</term>
<term>Maryland cancer center</term>
<term>Murine erythroleukemia cells</term>
<term>National cancer institute</term>
<term>Oral cavity</term>
<term>Periodontal disease status</term>
<term>Pharmacokinetic study</term>
<term>Pharmacologic study</term>
<term>Plasma concentrations</term>
<term>Plasma hmba concentrations</term>
<term>Proc natl acad</term>
<term>Saliva</term>
<term>Salivary</term>
<term>Salivary concentrations</term>
<term>Salivary hmba concentrations</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Summary: Salivary and plasma concentrations of hexamethylene bisacetamide (HMBA) were studied to determine (1) how the concentrations of HMBA achieved in saliva compared with those required to induce differentiation in vitro, and (2) whether saliva might substitute for plasma as a biologic fluid on which to base dosage adjustment. Plasma and expectorated saliva were collected concomitantly from 16 patients receiving 5-day continuous infusions of HMBA. The concentrations of HMBA in each fluid were determined by gas chromatography. The patients displayed a range of periodontal disease from gingivitis to complete edentia, but periodontal disease status did not appear to influence the salivary behavior of HMBA, which mirrored that of the drug in plasma, with concentrations of HMBA increasing in both fluids during the first 12–16 h of infusion. Between 24 and 120 h, HMBA concentrations in saliva and plasma remained constant. In some patients, salivary HMBA concentrations lagged behind those in plasma during the first 6–8 h of infusion, but after that the salivary HMBA concentrations approximated those in the plasma. Salivary concentrations of HMBA between 0.96 and 2.56 mM were associated with nontoxic plasma concentrations of HMBA. Therefore, in patients with restricted venous access, saliva might be a suitable substitute for plasma if adaptive control-dosing schemes for HMBA are employed. Moreover, the concentrations of HMBA in saliva bathing the oral cavity are quantitatively comparable to those required for induction of cell differentiation in vitro.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Conley, Barbara A" sort="Conley, Barbara A" uniqKey="Conley B" first="Barbara A." last="Conley">Barbara A. Conley</name>
</region>
<name sortKey="Conley, Barbara A" sort="Conley, Barbara A" uniqKey="Conley B" first="Barbara A." last="Conley">Barbara A. Conley</name>
<name sortKey="Egorin, Merrill J" sort="Egorin, Merrill J" uniqKey="Egorin M" first="Merrill J." last="Egorin">Merrill J. Egorin</name>
<name sortKey="Egorin, Merrill J" sort="Egorin, Merrill J" uniqKey="Egorin M" first="Merrill J." last="Egorin">Merrill J. Egorin</name>
<name sortKey="Peterson, Douglas E" sort="Peterson, Douglas E" uniqKey="Peterson D" first="Douglas E." last="Peterson">Douglas E. Peterson</name>
<name sortKey="Sinibaldi, Victoria J" sort="Sinibaldi, Victoria J" uniqKey="Sinibaldi V" first="Victoria J." last="Sinibaldi">Victoria J. Sinibaldi</name>
<name sortKey="Zuhowski, Eleanor G" sort="Zuhowski, Eleanor G" uniqKey="Zuhowski E" first="Eleanor G." last="Zuhowski">Eleanor G. Zuhowski</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/EdenteV2/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00C055 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00C055 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    EdenteV2
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:ED1E082857C04018E4B5D84A96BCAE000213068C
   |texte=   Salivary concentrations of hexamethylene bisacetamide ( HMBA ) in patients receiving 5-day continuous infusions
}}

This area was generated with Dilib version V0.6.32.
Data generation: Thu Nov 30 15:26:48 2017. Site generation: Tue Mar 8 16:36:20 2022

	Serveur d'exploration sur le patient édenté
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le patient édenté

Salivary concentrations of hexamethylene bisacetamide ( HMBA ) in patients receiving 5-day continuous infusions

Salivary concentrations of hexamethylene bisacetamide ( HMBA ) in patients receiving 5-day continuous infusions

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri